Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 31, 2017
NEWTON, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
-
Jan 3, 2017
NEWTON, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Dec 15, 2016- Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS -
NEWTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Target ALS Foundation, a non-profit...
-
Dec 5, 2016- STOMP Data Continues to Demonstrate High Response Rates in Patients with Heavily Pretreated Multiple Myeloma When Selinexor Is Combined with Bortezomib and Pomalidomide -
NEWTON, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from the Phase 1b...
-
Dec 4, 2016- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia -
NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from the Phase 2 SAIL study,...
-
Dec 4, 2016- Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -
NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from its Phase 2b STORM study...
-
Nov 30, 2016
NEWTON, Mass. and NORWALK, Conn., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, together with the Multiple Myeloma Research...
-
Nov 10, 2016
NEWTON, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Nov 7, 2016− Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Data Readout —
NEWTON, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2016...
-
Nov 3, 2016- Diverse Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -
NEWTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 21 abstracts have been selected for...